Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Ref Type abstract
Authors Musa Yilmaz, Muharrem Muftuoglu, Courtney D. DiNardo, Tapan M. Kadia, Marina Y. Konopleva, Gautam Borthakur, Naveen Pemmaraju, Nicholas J. Short, Yesid Alvarado Valero, Abhishek Maiti, Lucia Masarova, Guillermo Montalban-Bravo, Carissa Jurisprudencia, Allison Pike, Sanam Loghavi, Keyur P. Patel, Guilin Tang, Jairo Matthews, Steven M. Kornblau, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Michael Andreeff, Naval Daver
Title Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
Abstract Text Background: Patients (pts) newly diagnosed with FLT3-ITD mutated (m) acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy (IC) experience poor outcomes (Konopleva et al. 2022, Clin. Can. Res.). These patients have a median overall survival (OS) of 9.9 months when treated with the standard of care regimen (azacitidine and venetoclax). Aims: We evaluated the safety and efficacy of the triple combination of Quizartinib (Quiz), Venetoclax (VEN), and decitabine (DAC) in pts with relapsed/refractory (R/R) or newly diagnosed FLT3-ITDm AML. Methods: The study included a frontline cohort of pts ineligible for IC and an R/R cohort of pts who had received ≤ 5 prior treatments for AML (up to salvage 5). On Day 14, all pts underwent bone marrow (BM) evaluation, and VEN (400 mg/day or equivalent with azole) was discontinued on Day 14 for pts with BM blasts ≤ 5% (or marrow aplasia/hypocellularity). Pts with Day 14 BM blast >5% continued VEN for 21 days during cycle 1, followed by administration from days 1 to 14 in subsequent cycles, with further dose reductions based on count recovery. All pts received 10 days of DAC (20 mg/m2) for induction, followed by 5-day DAC in subsequent cycles. Quiz (30 or 40 mg/day) was continuously administered daily. Results: A total of 50 pts were enrolled, including 40 R/R and 10 newly FLT3-ITD mutated AML pts (Table 1). Among the 40 R/R AML pts (median 3 [range 1-5] prior AML therapies), 85% had received ≥1 prior FLT3 inhibitors (FLT3i's), with 78% having prior exposure to gilteritinib, and 40% having undergone prior allogeneic stem cell transplantation (ASCT). The rates of CRc, CR+CRi, measurable residual disease (MRD) negativity by multicolor flow cytometry (MFC, sensitivity 10 -4), and FLT3-PCR (sensitivity 10 -2 - 10 -3) negativity among the 40 R/R pts were 68%, 33%, 29% (7/24), and 36% (8/22), respectively (Table 2). The median number of cycles required to achieve a response was 1 (range 1-2). The 60-day mortality rate was 0%. With a median follow-up of 33 months, the median OS was 7.1 months, and the 1-year OS rate was 22% in this predominantly gilteritinib-exposed R/R cohort. Among the 31/40 prior gilteritinib exposed pts the CRc, CR+CRi, median OS and 1-year survival were 65%, 23%, 6.9 month, and 21%. Among the 9/10 prior gilteritinib naïve pts the CRc, CR+CRi, median OS and 1-year survival were 77%, 66%, 10.3 months and 25%. Among the newly diagnosed AML, all achieved CRc (7 CR, 3 CRi), with 9/10 (90%) and 7/9 (78%) evaluable responders being FLT3-PCR and MFC negative, respectively. All 10 pts achieved BM <5% or aplasia/hypocellularity on C1D14. With a median follow-up of 15 months, the median OS was not reached. No pts experienced dose-limiting toxicity (DLT) with Quiz 30 mg/day; however, with Quiz 40 mg/day, the first 2 pts treated developed hematologic DLT (grade 4 neutropenia with a <5% cellular bone marrow with no residual AML lasting ≥42 days). Consequently, Quiz 30 mg/day was declared the RP2D for this combination. In the R/R cohort, grade ≥3 non-hematologic toxicities regardless of attribution, occurring in >10% of pts, included pneumonia (73%), neutropenic fever (53%), sepsis (18%), bacteremia (15%), other infections involving the skin (18%), and gastrointestinal tract (13%). The incidence of grade ≥3 non-hematologic toxicities was less frequent in the frontline cohort, with pneumonia (40%), neutropenic fever (50%), sepsis (10%), bacteremia (20%), and no grade 3 QTcF prolongations observed. The median recovery times for absolute neutrophil count (ANC > 500/μL) and platelet (>50 x 109/L) were 43 days [13-138] and 49 days [21-67] for the R/R cohort, and 40 days [28-56] and 40 days [22-46] for the frontline cohort, respectively. In the frontline cohort, at the last follow-up, 7 pts were in complete remission (CR), 2 ps died with relapsed AML, and 1 pt died in remission postASCT. Among the 40 pts in the R/R cohort, 9 were still alive (7 in CR, 2 with relapsed disease), while 31 pts died (5 deaths in CR, 26 due to relapsed/refractory leukemia). Conclusion: The combination of DAC + VEN + Quiz demonstrated activity in heavily pretreated and prior FLT3i-exposed (including 78% with prior gilteritinib exposure) R/R FLT3-ITDm pts, with a CRc rate of 68% and a median OS of 7.1 months. In the frontline setting, all pts achieved CRc with no early mortality, median count recovery of 40 days, and median OS not reached. The study continues to accrue, and updated results will be reported at the meeting.


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 exon 14 ins acute myeloid leukemia predicted - sensitive Decitabine + Quizartinib + Venetoclax Phase Ib/II Actionable In a Phase I/II trial, treatment with the combination of Vanflyta (quizartinib), Venclexta (venetoclax), and Dacogen (decitabine) resulted in a composite complete remission (CRc) rate of 68% (27/40), a median overall survival (OS) of 7.1 months, and a 1-year OS rate of 22% in relapsed/refractory acute myeloid leukemia patients with FLT3-ITD mutations, and in the frontline setting, the combination treatment resulted in a CRc of 100% (10/10) (Blood (2023) 142 (Supplement 1): 158; NCT03661307). detail...